Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Bitcoin USD

    63,159.75
    -1,121.19 (-1.74%)
     

  • CMC Crypto 200

    1,314.00
    -82.54 (-5.91%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • Dow

    38,239.66
    +153.86 (+0.40%)
     

  • Nasdaq

    15,927.90
    +316.14 (+2.03%)
     

  • Gold

    2,349.60
    +7.10 (+0.30%)
     

  • Crude Oil

    83.66
    +0.09 (+0.11%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Calithera (CALA) Soars: Stock Adds 9.4% in Session

Zacks Equity Research

Calithera Biosciences, Inc. CALA was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 63.1% in the past one-month time frame.

The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Calithera. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Calithera currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Calithera Biosciences, Inc. Price

Calithera Biosciences, Inc. Price
Calithera Biosciences, Inc. Price

Calithera Biosciences, Inc. price | Calithera Biosciences, Inc. Quote

ADVERTISEMENT

A better-ranked stock in the Medical - Drugs industry is CytoDyn Inc. CYDY, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CytoDyn Inc. (CYDY) : Free Stock Analysis Report
 
Calithera Biosciences, Inc. (CALA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research